This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
What's in the Cards for Perrigo (PRGO) This Earnings Season?
by Zacks Equity Research
Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.
Amarin (AMRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $16.42 in the latest trading session, marking a +0.37% move from the prior day.
Is a Beat in Store for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) third-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
Implied Volatility Surging for Amarin (AMRN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Is Amarin Corporation (AMRN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (AMRN) Outperforming Other Medical Stocks This Year?
Biotech Stock Roundup: Amgen's Enbrel Patent Win, AMRN's Setback & More
by Zacks Equity Research
Key highlights of the past week include collaborations, and other regulatory and pipeline news.
Amarin (AMRN) Beats Earnings & Beats Revenues in Q2
by Zacks Equity Research
Amarin beats estimates for both earnings and revenues in the second quarter of 2019. Shares up.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa is expected to drive sales in the second quarter.
Implied Volatility Surging for Amarin (AMRN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Issues Update on Q2 Sales, Raises '19 Guidance
by Zacks Equity Research
Amarin announces strong preliminary sales of Vascepa in the second quarter. The company increases sales guidance for 2019.
Company News for Jul 3, 2019
by Zacks Equity Research
Companies In The News Are: DAL, AMRN, HRS, ADP
Amarin Rises on Priority Review for Vascepa Label Expansion
by Zacks Equity Research
Amarin's (AMRN) label expansion application for hypertriglyceridemia drug, Vascepa, gets priority review from the FDA.
Options Traders Expect Huge Moves in Amarin (AMRN) Stock
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Beats Estimates for Earnings & Revenues in Q1
by Zacks Equity Research
Amarin (AMRN) surpasses estimates for earnings and sales in the first quarter of 2019.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Amarin (AMRN) closed at $18.99, marking a +1.06% move from the previous day.
Amarin (AMRN) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $19.75 in the latest trading session, marking a +0.71% move from the prior day.
Implied Volatility Surging for Amarin (AMRN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Misses Earnings & Beats Revenues in Q4
by Zacks Equity Research
Amarin misses earnings estimates while it beats sales in the fourth quarter of 2018.
Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the fourth quarter.
Amarin (AMRN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $17.35 in the latest trading session, marking a +1.46% move from the prior day.
Amarin (AMRN) Stock Moves -0.49%: What You Should Know
by Zacks Equity Research
Amarin (AMRN) closed at $16.15 in the latest trading session, marking a -0.49% move from the prior day.
Do Options Traders Know Something About Amarin (AMRN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Amarin (AMRN) stock based on the movements in the options market lately.
Amarin (AMRN) Stock Up on Rumors of Acquisition by Pfizer
by Zacks Equity Research
Amarin (AMRN) shares rally on rumors of its potential; acquisition by large pharmaceutical company, Pfizer. Speculations are rife about rising M&A activity in the pharma space.